The Company

Arthrosurface® Inc was organized in 2001 to develop surgical alternatives for the treatment of orthopedic joint disease. Arthrosurface's efforts are focused on the development of methods to repair articular cartilage damage of the major joints including knees, hips, toes and shoulders using minimal-access surgical procedures. In 2004, the Company commercially launched it first USA products focused on the Shoulder and, in the same year, it began commercialization in Europe with its shoulder and focal knee product lines.  Arthrosurface has since expanded its product offering to include resurfacing products for the toe, knee cap joint (patello-femoral), partial knees and, most recently, a total shoulder system. 

Arthrosurface was incubated and spun off by STD Med, Inc. a medical device manufacturing company owned by several of the founding shareholders of Arthrosurface. STD Med is an "original equipment manufacturer" ("OEM") for a number of medical device companies with a strong history of medical product development and enhancement. In addition, STD Med is registered as a medical device manufacturer with the U.S. Food and Drug Administration ("FDA") and is certified under ISO 9001 and ISO 13485. STD Med has successfully spun out 4 companies since 2000 of which two of the four, Angiolink and Spirus Medical, have gone on to be acquired by Medtronic and Olympus, respectively.  In 2003, Arthrosurface entered into an agreement with Boston Millennia Partners, a prestigious and well established Venture Capital company to provide funding and expertise.

The Arthrosurface team is made of experienced individuals in the medical device industry and there are now over 3,000 surgeons using the products in over 25 countries.  Just recently, Arthrosurface launched into the Mexican market and new markets are planned for the expansion in 2012.